Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Legal
News

‘First Cryptocurrency Insider-Trading Case Yields 10-Month Prison Term’ – Reuters

https://www.reuters.com/legal/ex-coinbase-managers-brother-sentenced-10-months-insider-trading-case-2023-01-10/

byBenzinga Newsdesk

January 10, 2023

1 minute read

https://www.reuters.com/legal/ex-coinbase-managers-brother-sentenced-10-months-insider-trading-case-2023-01-10/

Spirit Airlines, ATP Flight School Launch New Program For Next Generation Of Pilots

By Benzinga Newsdesk

Today, 8:41 PM

Spirit Airlines (NYSE:SAVE) today announced its partnership with the nation's largest flight school, Jacksonville-based ATP Flight School. The new Spirit Direct Program will expand the carrier's

SAVE

Raymond James Initiates Coverage On GLOBALFOUNDRIES with Outperform Rating, Announces Price Target of $80

By Benzinga Newsdesk

Today, 8:41 PM

Raymond James analyst Chris Caso initiates coverage on GLOBALFOUNDRIES (NASDAQ:GFS) with a Outperform rating and announces Price Target of $80.

GFS

News

Asensus Surgical Granted U.S. Patent #11,199,545 ‘Hydraulic instrument drive system for minimally invasive surgery’

By Charles Gross

Today, 8:41 PM

View Patent Here

ASXC

FDA
News

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i

By Benzinga Newsdesk

Today, 8:41 PM

Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples Increase in the ratio of glycosylated αDG to total

BBIO

‘First Cryptocurrency Insider-Trading Case Yields 10-Month Prison Term’ – Reuters

Related Posts

Spirit Airlines, ATP Flight School Launch New Program For Next Generation Of Pilots

Raymond James Initiates Coverage On GLOBALFOUNDRIES with Outperform Rating, Announces Price Target of $80

Asensus Surgical Granted U.S. Patent #11,199,545 ‘Hydraulic instrument drive system for minimally invasive surgery’

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i